Scott A. Gangloff - 15 Aug 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Technology Officer
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 15 Aug 2025
Net transactions value: +$51,012
Form type: 4
Filing time: 19 Aug 2025, 21:32:05 UTC
Previous filing: 02 Jul 2025
Next filing: 09 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gangloff Scott A.	Chief Technology Officer	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO	/s/ Jonathan Young, Attorney-in-Fact	19 Aug 2025	0001663253

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$51,012	+2,600	+11%	$19.62	26,351	15 Aug 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock option (Right to Buy)	Options Exercise	$0	-2,600	-13%	$0.000000	17,784	15 Aug 2025	Common Stock	20,384	$19.62	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.